🚀 VC round data is live in beta, check it out!
Creo Medical Group Valuation Multiples
Discover revenue and EBITDA valuation multiples for Creo Medical Group and similar public comparables like Xtant Medical, Meditera, Nexstim, Applied BioCode and more.
Creo Medical Group Overview
About Creo Medical Group
Creo Medical Group PLC is a medical device company engaged in providing services in the field of surgical endoscopy. The company has developed a platform called Croma which is an electrosurgical platform to deliver microwave and bipolar radiofrequency through a single accessory port. The reportable segment of the company is the research and development of electrosurgical medical devices relating to the field of surgical endoscopy. Geographically, the company generates a majority of its revenue from United Kingdom and the rest from Europe and the rest of the world.
Founded
2016
HQ
Employees
274
Website
Financials (LTM)
EV
$59M
Creo Medical Group Financials
Creo Medical Group reported last 12-month revenue of $9M and negative EBITDA of ($17M).
In the same LTM period, Creo Medical Group generated $5M in gross profit, ($17M) in EBITDA losses, and had net loss of ($11M).
Revenue (LTM)
Creo Medical Group P&L
In the most recent fiscal year, Creo Medical Group reported revenue of $5M and EBITDA of ($30M).
Creo Medical Group expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $9M | XXX | $5M | XXX | XXX | XXX |
| Gross Profit | $5M | XXX | $3M | XXX | XXX | XXX |
| Gross Margin | 55% | XXX | 47% | XXX | XXX | XXX |
| EBITDA | ($17M) | XXX | ($30M) | XXX | XXX | XXX |
| EBITDA Margin | (182%) | XXX | (560%) | XXX | XXX | XXX |
| EBIT Margin | (120%) | XXX | (679%) | XXX | XXX | XXX |
| Net Profit | ($11M) | XXX | ($37M) | XXX | XXX | XXX |
| Net Margin | (121%) | XXX | (695%) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Creo Medical Group Stock Performance
Creo Medical Group has current market cap of $81M, and enterprise value of $59M.
Market Cap Evolution
Creo Medical Group's stock price is $0.20.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $59M | $81M | 0.4% | XXX | XXX | XXX | $-0.09 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialCreo Medical Group Valuation Multiples
Creo Medical Group trades at 6.5x EV/Revenue multiple, and (3.6x) EV/EBITDA.
EV / Revenue (LTM)
Creo Medical Group Financial Valuation Multiples
As of April 8, 2026, Creo Medical Group has market cap of $81M and EV of $59M.
Equity research analysts estimate Creo Medical Group's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Creo Medical Group has a P/E ratio of (7.3x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $81M | XXX | $81M | XXX | XXX | XXX |
| EV (current) | $59M | XXX | $59M | XXX | XXX | XXX |
| EV/Revenue | 6.5x | XXX | 11.0x | XXX | XXX | XXX |
| EV/EBITDA | (3.6x) | XXX | (2.0x) | XXX | XXX | XXX |
| EV/EBIT | (5.4x) | XXX | (1.6x) | XXX | XXX | XXX |
| EV/Gross Profit | 11.8x | XXX | 23.4x | XXX | XXX | XXX |
| P/E | (7.3x) | XXX | (2.2x) | XXX | XXX | XXX |
| EV/FCF | (3.2x) | XXX | (2.0x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Creo Medical Group Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Creo Medical Group Margins & Growth Rates
Creo Medical Group's revenue in the last 12 month grew by 57%.
Creo Medical Group's revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $0.1M for the same period.
Creo Medical Group's rule of 40 is (41%) (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Creo Medical Group's rule of X is 42% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Creo Medical Group Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 57% | XXX | 49% | XXX | XXX | XXX |
| EBITDA Margin | (182%) | XXX | (560%) | XXX | XXX | XXX |
| EBITDA Growth | (39%) | XXX | (39%) | XXX | XXX | XXX |
| Rule of 40 | — | XXX | (41%) | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 42% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.0M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.1M | XXX | XXX | XXX |
| G&A Expenses to Revenue | 320% | XXX | 758% | XXX | XXX | XXX |
| R&D Expenses to Revenue | 40% | XXX | 164% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 760% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Creo Medical Group Public Comps
See public comps and valuation multiples for other Medical Devices comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Xtant Medical | XXX | XXX | XXX | XXX | XXX | XXX |
| Meditera | XXX | XXX | XXX | XXX | XXX | XXX |
| Nexstim | XXX | XXX | XXX | XXX | XXX | XXX |
| Applied BioCode | XXX | XXX | XXX | XXX | XXX | XXX |
| Medicalgorithmics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Creo Medical Group M&A Activity
Creo Medical Group acquired XXX companies to date.
Last acquisition by Creo Medical Group was on XXXXXXXX, XXXXX. Creo Medical Group acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Creo Medical Group
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialCreo Medical Group Investment Activity
Creo Medical Group invested in XXX companies to date.
Creo Medical Group made its latest investment on XXXXXXXX, XXXXX. Creo Medical Group invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Creo Medical Group
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Creo Medical Group
| When was Creo Medical Group founded? | Creo Medical Group was founded in 2016. |
| Where is Creo Medical Group headquartered? | Creo Medical Group is headquartered in United Kingdom. |
| How many employees does Creo Medical Group have? | As of today, Creo Medical Group has over 274 employees. |
| Who is the CEO of Creo Medical Group? | Creo Medical Group's CEO is Craig Jonathan Gulliford. |
| Is Creo Medical Group publicly listed? | Yes, Creo Medical Group is a public company listed on London Stock Exchange. |
| What is the stock symbol of Creo Medical Group? | Creo Medical Group trades under CREO ticker. |
| When did Creo Medical Group go public? | Creo Medical Group went public in 2016. |
| Who are competitors of Creo Medical Group? | Creo Medical Group main competitors are Xtant Medical, Meditera, Nexstim, Applied BioCode. |
| What is the current market cap of Creo Medical Group? | Creo Medical Group's current market cap is $81M. |
| What is the current revenue of Creo Medical Group? | Creo Medical Group's last 12 months revenue is $9M. |
| What is the current revenue growth of Creo Medical Group? | Creo Medical Group revenue growth (NTM/LTM) is 57%. |
| What is the current EV/Revenue multiple of Creo Medical Group? | Current revenue multiple of Creo Medical Group is 6.5x. |
| Is Creo Medical Group profitable? | No, Creo Medical Group is not profitable. |
| What is the current EBITDA of Creo Medical Group? | Creo Medical Group has negative EBITDA and is not profitable. |
| What is Creo Medical Group's EBITDA margin? | Creo Medical Group's last 12 months EBITDA margin is (182%). |
| What is the current EV/EBITDA multiple of Creo Medical Group? | Current EBITDA multiple of Creo Medical Group is (3.6x). |
| What is the current FCF of Creo Medical Group? | Creo Medical Group's last 12 months FCF is ($19M). |
| What is Creo Medical Group's FCF margin? | Creo Medical Group's last 12 months FCF margin is (204%). |
| What is the current EV/FCF multiple of Creo Medical Group? | Current FCF multiple of Creo Medical Group is (3.2x). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.